Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents (HGG-CilMetro)

This study has been terminated.
(due to an altered benefit/risk assessment.)
Merck KGaA
Information provided by (Responsible Party):
Christof Kramm, Martin-Luther-Universität Halle-Wittenberg Identifier:
First received: January 11, 2012
Last updated: June 26, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2014
  Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: May 26, 2015